Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunization against tumor cell surface complement-regulatory proteins.

L G Durrant1, I Spendlove

  • 1Academic Unit of Clinical Oncology, City Hospital, Nottingham, UK. Lindy.Durrant@nottingham.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus.

Scientific reports·2020
Same author

Post-translational modifications such as citrullination are excellent targets for cancer therapy.

Seminars in immunology·2020
Same author

Molecular expression patterns in the synovium and their association with advanced symptomatic knee osteoarthritis.

Osteoarthritis and cartilage·2019
Same author

Elevation of alanine transaminase and markers of liver fibrosis after a mixed meal challenge in individuals with type 2 diabetes.

Digestive diseases and sciences·2012
Same author

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.

British journal of cancer·2012
Same author

Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Clinical and experimental immunology·2012

Targeting complement regulatory proteins on cancer cells can restore sensitivity to immune attack. Carefully designed vaccines targeting these proteins show promise for cancer therapy with minimal toxicity.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • The complement system is a crucial part of innate immunity, mediating cell lysis and inflammation.
  • Cancer cells often evade complement-mediated destruction by altering complement regulatory proteins (CRPs).
  • This immune evasion limits the efficacy of antibody-based cancer therapies.

Purpose of the Study:

  • To investigate targeting complement regulatory proteins (CD55, CD46, CD59) as a therapeutic strategy in cancer.
  • To explore the potential of cancer vaccines that specifically target overexpressed CRPs on tumor cells.
  • To evaluate the safety and efficacy of anti-idiotypic antibodies mimicking CRPs.

Main Methods:

  • Analysis of CRP expression patterns in cancer.
  • Development and testing of anti-idiotypic antibodies mimicking CRPs.

Related Experiment Videos

  • Assessing immune responses and toxicity in preclinical and clinical settings.

    • Main Results:

    • Deregulation of CD55, CD46, and CD59 is common in cancer, conferring resistance to complement.
    • A human anti-idiotypic antibody mimicking CD55 showed success in colorectal cancer and osteosarcoma patients.
    • 70% of patients developed CD55-specific immune responses without toxicity.

    Conclusions:

    • Targeting CRPs offers a promising avenue for cancer therapy, potentially restoring complement-mediated lysis.
    • Cancer vaccines designed against tumor-specific CRPs can induce targeted immune responses.
    • Careful vaccine design is essential to avoid targeting CRPs on normal tissues, preventing adverse effects.